ArticleOncotarget2015

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).

David M Goldenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.